Microneedle-mediated delivery of viral vectored vaccines

References

• WHO. Global vaccine action plan. 2011–2020. Available from: http://www.who.int/immunization/global_vaccine_action_plan/GVAP_doc_2011_2020/en/
   Google Scholar
• Bennett V. Vaccination is a lifelong benefit – make every contact count. Available from: https://publichealthmatters.blog.gov.uk/2016/04/28/vaccination-is-a-lifelong-benefit-make-every-contact-count/2016
   Google Scholar
• Aronson SM. Two stealth triumphs in global health. Med Health R I. 2012 Feb;95(2):35.
   PubMedGoogle Scholar
• Minor P. The polio endgame. Hum Vaccin Immunother. 2014;10(7):2106–2108.
   PubMedGoogle Scholar
• Pulendran B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat Rev Immunol. 2009 Oct;9(10):741–747.
   PubMed Web of Science ®Google Scholar
• Miller MA, Pisani E. The cost of unsafe injections. Bull World Health Organ. 1999;77(10):808–811.
   PubMed Web of Science ®Google Scholar
• Hegde NR, Kaveri SV, Bayry J. Recent advances in the administration of vaccines for infectious diseases: microneedles as painless delivery devices for mass vaccination. Drug Discov Today. 2011 Dec;16(23–24):1061–1068.
   PubMed Web of Science ®Google Scholar
• Koutsonanos DG, Del Pilar Martin M, Zarnitsyn VG, et al. Transdermal influenza immunization with vaccine-coated microneedle arrays. PLoS One. 2009;4(3):e4773.
   PubMed Web of Science ®Google Scholar
• Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol. 2011 Jun;12(6):509–517.
   PubMed Web of Science ®Google Scholar
• Huo Y, Wan X, Ling T, et al. Prevailing Sydney like Norovirus GII.4 VLPs induce systemic and mucosal immune responses in mice. Mol Immunol. 2015 Dec;68(2Pt A):367–372.
   PubMed Web of Science ®Google Scholar
• Jackson EM, Herbst-Kralovetz MM, Miyaji EN. Intranasal vaccination with murabutide enhances humoral and mucosal immune responses to a virus-like particle vaccine. PLoS One. 2012;7(7):e41529.
   PubMed Web of Science ®Google Scholar
• Oien NL, Brideau RJ, Walsh EE, et al. Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit. Vaccine. 1994 Jun;12(8):731–735.
   PubMed Web of Science ®Google Scholar
• Liang Y, Ma S, Yang Z, et al. Immunogenicity and safety of a novel formalin-inactivated and alum-adjuvanted candidate subunit vaccine for mumps. Vaccine. 2008 Aug 5;26(33):4276–4283.
   PubMed Web of Science ®Google Scholar
• Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 2004 Oct;82(5):488–496.
   PubMed Web of Science ®Google Scholar
• McKee AS, Munks MW, Marrack P. How do adjuvants work? Important considerations for new generation adjuvants. Immunity. 2007 Nov;27(5):687–690.
   PubMed Web of Science ®Google Scholar
• Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity. 2010 Oct 29;33(4):492–503.
   PubMed Web of Science ®Google Scholar
• Pollock KG, Conacher M, Wei XQ, et al. Interleukin-18 plays a role in both the alum-induced T helper 2 response and the T helper 1 response induced by alum-adsorbed interleukin-12. Immunology. 2003 Feb;108(2):137–143.
   PubMed Web of Science ®Google Scholar
• Lycke N. Targeted vaccine adjuvants based on modified cholera toxin. Curr Mol Med. 2005 Sep;5(6):591–597.
   PubMed Web of Science ®Google Scholar
• Lee J-B, Jang J-E, Song MK, et al. Intranasal delivery of cholera toxin induces th17-dominated T-cell response to bystander antigens. PLoS One. 2009;4(4):e5190.
   PubMed Web of Science ®Google Scholar
• Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007 Sep 27;449(7161):419–426.
   PubMed Web of Science ®Google Scholar
• Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000;18:767–811.
   PubMed Web of Science ®Google Scholar
• Steinman RM. Some interfaces of dendritic cell biology. Apmis. 2003 Jul-Aug;111(7–8):675–697.
   PubMed Web of Science ®Google Scholar
• Shortman K, Naik SH. Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol. 2007 Jan;7(1):19–30.
   PubMed Web of Science ®Google Scholar
• Schlitzer A, Ginhoux F. Organization of the mouse and human DC network. Curr Opin Immunol. 2014 Feb;26:90–99.
   PubMed Web of Science ®Google Scholar
• Ginhoux F, Ng LG, Merad M. Understanding the murine cutaneous dendritic cell network to improve intradermal vaccination strategies. Curr Top Microbiol Immunol. 2012;351:1–24.
   PubMed Web of Science ®Google Scholar
• Haniffa M, Shin A, Bigley V, et al. Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells. Immunity. 2012 Jul 27;37(1):60–73.
   PubMed Web of Science ®Google Scholar
• De Panfilis G, Soligo D, Manara GC, et al. Adhesion molecules on the plasma membrane of epidermal cells. I. Human resting Langerhans cells express two members of the adherence-promoting CD11/CD18 family, namely, H-Mac-1 (CD11b/CD18) and gp 150,95 (CD11c/CD18). J Invest Dermatol. 1989 Jul;93(1):60–69.
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998 Mar 19; 392(6673):245–252.
   PubMed Web of Science ®Google Scholar
• Ohl L, Mohaupt M, Czeloth N, et al. CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity. 2004 Aug;21(2):279–288.
   PubMed Web of Science ®Google Scholar
• Sparwasser T, Koch ES, Vabulas RM, et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol. 1998 Jun;28(6):2045–2054.
   PubMed Web of Science ®Google Scholar
• Young JW, Koulova L, Soergel SA, et al. The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro. J Clin Invest. 1992 Jul;90(1):229–237.
   PubMed Web of Science ®Google Scholar
• Coquerelle C, Moser M. DC subsets in positive and negative regulation of immunity. Immunol Rev. 2010 Mar;234(1):317–334.
   PubMed Web of Science ®Google Scholar
• Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol. 2003 Dec;3(12):984–993.
   PubMed Web of Science ®Google Scholar
• Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature. 2007 Oct 18;449(7164):819–826.
   PubMed Web of Science ®Google Scholar
• Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol. 2001;19:47–64.
   PubMed Web of Science ®Google Scholar
• Jung S, Unutmaz D, Wong P, et al. In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity. 2002 Aug;17(2):211–220.
   PubMed Web of Science ®Google Scholar
• Kurts C. Cross-presentation: inducing CD8 T cell immunity and tolerance. J Mol Med (Berl). 2000;78(6):326–332.
   PubMed Web of Science ®Google Scholar
• Gutierrez-Martinez E, Planes R, Anselmi G, et al. Cross-presentation of cell-associated antigens by MHC class i in dendritic cell subsets. Front Immunol. 2015;6:363.
   PubMed Web of Science ®Google Scholar
• Jackson DA, Symons RH, Berg P. Biochemical method for inserting new genetic information into DNA of Simian Virus 40: circular SV40 DNA molecules containing lambda phage genes and the galactose operon of Escherichia coli. Proc Natl Acad Sci U S A. 1972 Oct;69(10):2904–2909.
   PubMed Web of Science ®Google Scholar
• Moss B, Smith GL, Gerin JL, et al. Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature. 1984 Sep 6-11;311(5981):67–69.
   PubMed Web of Science ®Google Scholar
• Choi Y, Chang J. Viral vectors for vaccine applications. Clin Exp Vaccine Res. 2013 Jul;2(2):97–105.
   PubMedGoogle Scholar
• Casimiro DR, Chen L, Fu TM, et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol. 2003 June 1;77(11):6305–6313.
   PubMed Web of Science ®Google Scholar
• Khattar SK, Nayak B, Kim S, et al. Evaluation of the replication, pathogenicity, and immunogenicity of avian paramyxovirus (APMV) serotypes 2, 3, 4, 5, 7, and 9 in rhesus macaques. Plos One. 2013;8(10):e75456.
   PubMed Web of Science ®Google Scholar
• Abbink P, Maxfield LF, Ng’ang’a D, et al. Construction and evaluation of novel rhesus monkey adenovirus vaccine vectors. J Virol. 2015 Feb 1;89(3):1512–1522.
   PubMed Web of Science ®Google Scholar
• Ura T, Okuda K, Shimada M. Developments in viral vector-based vaccines. Vaccines (Basel). 2014;2(3):624–641.
   PubMedGoogle Scholar
• Draper SJ, Heeney JL. Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol. 2010 Jan;8(1):62–73.
   PubMed Web of Science ®Google Scholar
• Naslund TI, Uyttenhove C, Nordstrom EK, et al. Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor. J Immunol. 2007 Jun 1;178(11):6761–6769.
   PubMed Web of Science ®Google Scholar
• Gabitzsch ES, Xu Y, Yoshida LH, et al. Novel adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity. Vaccine. 2009 Oct 30;27(46):6394–6398.
   PubMed Web of Science ®Google Scholar
• Shott JP, McGrath SM, Pau MG, et al. Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice. Vaccine. 2008 Jun 2;26(23):2818–2823.
   PubMed Web of Science ®Google Scholar
• Gurwith M, Lock M, Taylor EM, et al. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis. 2013 Mar;13(3):238–250.
   PubMed Web of Science ®Google Scholar
• Barnes E, Folgori A, Capone S, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med. 2012 Jan 4;4(115):115ra1.
   PubMed Web of Science ®Google Scholar
• De Cassan SC, Draper SJ. Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets. Expert Rev Vaccines. 2013 Apr;12(4):365–378.
   PubMed Web of Science ®Google Scholar
• Sutter G, Staib C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord. 2003 Sep;3(3):263–271.
   PubMedGoogle Scholar
• Price PJR, Torres-Domínguez LE, Brandmüller C, et al. Modified Vaccinia virus Ankara: innate immune activation and induction of cellular signalling. Vaccine. 2013 Sep 6;31(39):4231–4234.
   PubMed Web of Science ®Google Scholar
• Zhu J, Martinez J, Huang X, et al. Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta. Blood. 2007 Jan 15;109(2):619–625.
   PubMed Web of Science ®Google Scholar
• Bakari M, Aboud S, Nilsson C, et al. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine. 2011 Oct 26;29(46):8417–8428.
   PubMed Web of Science ®Google Scholar
• Garcia F, Bernaldo De Quiros JC, Gomez CE, et al. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: a phase I clinical trial (RISVAC02). Vaccine. 2011 Oct 26;29(46):8309–8316.
   PubMed Web of Science ®Google Scholar
• Gomez CE, Najera JL, Perdiguero B, et al. The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens. J Virol. 2011 Nov;85(21):11468–11478.
   PubMed Web of Science ®Google Scholar
• Berthoud TK, Hamill M, Lillie PJ, et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis. 2011 Jan 1;52(1):1–7.
   PubMed Web of Science ®Google Scholar
• Cavenaugh JS, Awi D, Mendy M, et al. Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection. PLoS One. 2011;6(2):e14626.
   PubMed Web of Science ®Google Scholar
• Bejon P, Ogada E, Mwangi T, et al. Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS One. 2007;2(8):e707.
   PubMed Web of Science ®Google Scholar
• Tameris MD, Hatherill M, Landry BS, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 2013 Mar 23;381(9871):1021–1028.
   PubMed Web of Science ®Google Scholar
• Chan WM, Rahman MM, McFadden G. Oncolytic myxoma virus: the path to clinic. Vaccine. 2013 Sep 6;31(39):4252–4258.
   PubMed Web of Science ®Google Scholar
• Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009 Dec 3;361(23):2209–2220.
   PubMed Web of Science ®Google Scholar
• Davison AJ, Moss B. New vaccinia virus recombination plasmids incorporating a synthetic late promoter for high level expression of foreign proteins. Nucleic Acids Res. 1990 Jul 25;18(14):4285–4286.
   PubMed Web of Science ®Google Scholar
• Falivene J, Del Medico Zajac MP, Pascutti MF, et al. Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein. PLoS One. 2012;7(2):e32220.
   PubMed Web of Science ®Google Scholar
• Al-Zahrani S, Zaric M, McCrudden C, et al. Microneedle-mediated vaccine delivery: harnessing cutaneous immunobiology to improve efficacy. Expert Opin Drug Deliv. 2012 May;9(5):541–550.
   PubMed Web of Science ®Google Scholar
• Zaric M, Lyubomska O, Touzelet O, et al. Skin dendritic cell targeting via microneedle arrays laden with antigen-encapsulated poly-D,L-lactide-co-glycolide nanoparticles induces efficient antitumor and antiviral immune responses. ACS Nano. 2013 Mar 26;7(3):2042–2055.
   PubMed Web of Science ®Google Scholar
• Naik A, Kalia YN, Guy RH. Transdermal drug delivery: overcoming the skin’s barrier function. Pharm Sci Technolo Today. 2000 Sep 1;3(9):318–326.
   PubMedGoogle Scholar
• Garland MJ, Migalska K, Mahmood TM, et al. Microneedle arrays as medical devices for enhanced transdermal drug delivery. Expert Rev Med Devices. 2011 Jul;8(4):459–482.
   PubMed Web of Science ®Google Scholar
• Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev. 2012 Nov;64(14):1547–1568.
   PubMed Web of Science ®Google Scholar
• Donnelly RF, Majithiya R, Singh TR, et al. Design, optimization and characterisation of polymeric microneedle arrays prepared by a novel laser-based micromoulding technique. Pharm Res. 2011 Jan;28(1):41–57.
   PubMed Web of Science ®Google Scholar
• Chen X, Fernando GJ, Crichton ML, et al. Improving the reach of vaccines to low-resource regions, with a needle-free vaccine delivery device and long-term thermostabilization. J Control Release. 2011 Jun 30;152(3):349–355.
   PubMed Web of Science ®Google Scholar
• Henry S, McAllister DV, Allen MG, et al. Microfabricated microneedles: A novel approach to transdermal drug delivery. J Pharm Sci. 1999 Sep;88(9):948.
   PubMed Web of Science ®Google Scholar
• Kwon S-Y. In vitro evaluation of transdermal drug delivery by a micro-needle patch. 2004. Availble from: http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.494.6126&rep=rep1&type=pdf
   Google Scholar
• Prausnitz MR, Mikszta JA, Cormier M, et al. Microneedle-based vaccines. Curr Top Microbiol Immunol. 2009;333:369–393.
   PubMedGoogle Scholar
• Choi HJ, Yoo DG, Bondy BJ, et al. Stability of influenza vaccine coated onto microneedles. Biomaterials. 2012 May;33(14):3756–3769.
   PubMed Web of Science ®Google Scholar
• Choi HJ, Song JM, Bondy BJ, et al. Effect of osmotic pressure on the stability of whole inactivated influenza vaccine for coating on microneedles. PLoS One. 2015;10(7):e0134431.
   PubMed Web of Science ®Google Scholar
• Mistilis MJ, Joyce JC, Esser ES, et al. Long-term stability of influenza vaccine in a dissolving microneedle patch. Drug Deliv Transl Res. 2016 Feb 29. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Alcock R, Cottingham MG, Rollier CS, et al. Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass. Sci Transl Med. 2010 Feb 17;2(19):19ra12.
   PubMed Web of Science ®Google Scholar
• Bachy V, Hervouet C, Becker PD, et al. Langerin negative dendritic cells promote potent CD8+ T-cell priming by skin delivery of live adenovirus vaccine microneedle arrays. Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):3041–3046.
   PubMed Web of Science ®Google Scholar
• Chu LY, Ye L, Dong K, et al. Enhanced stability of inactivated influenza vaccine encapsulated in dissolving microneedle patches. Pharm Res. 2016 Apr;33(4):868–878.
   PubMed Web of Science ®Google Scholar
• Park SJ, Kim EH, Pascua PN, et al. Evaluation of heterosubtypic cross-protection against highly pathogenic H5N1 by active infection with human seasonal influenza A virus or trivalent inactivated vaccine immunization in ferret models. J Gen Virol. 2014 Apr;95(Pt 4):793–798.
   PubMed Web of Science ®Google Scholar
• Depelsenaire AC, Meliga SC, McNeilly CL, et al. Colocalization of cell death with antigen deposition in skin enhances vaccine immunogenicity. J Invest Dermatol. 2014 Sep;134(9):2361–2370.
   PubMed Web of Science ®Google Scholar
• Carey JB, Pearson FE, Vrdoljak A, et al. Microneedle array design determines the induction of protective memory CD8+ T cell responses induced by a recombinant live malaria vaccine in mice. PLoS One. 2011;6(7):e22442.
   PubMed Web of Science ®Google Scholar
• Becker PD, Hervouet C, Mason GM, et al. Skin vaccination with live virus vectored microneedle arrays induce long lived CD8(+) T cell memory. Vaccine. 2015 Sep 8;33(37):4691–4698.
   PubMed Web of Science ®Google Scholar
• Carey JB, Vrdoljak A, O’Mahony C, et al. Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route. Sci Rep. 2014;4:6154.
   PubMed Web of Science ®Google Scholar
• Pearson FE, O’Mahony C, Moore AC, et al. Induction of CD8(+) T cell responses and protective efficacy following microneedle-mediated delivery of a live adenovirus-vectored malaria vaccine. Vaccine. 2015 Jun 22;33(28):3248–3255.
   PubMed Web of Science ®Google Scholar
• DeMuth PC, Li AV, Abbink P, et al. Vaccine delivery with microneedle skin patches in nonhuman primates. Nat Biotechnol. 2013 Dec;31(12):1082–1085.
   PubMed Web of Science ®Google Scholar
• Van Der Maaden K, Sekerdag E, Jiskoot W, et al. Impact-insertion applicator improves reliability of skin penetration by solid microneedle arrays. Aaps J. 2014 Jul;16(4):681–684.
   PubMed Web of Science ®Google Scholar
• DeMuth PC, Min Y, Huang B, et al. Polymer multilayer tattooing for enhanced DNA vaccination. Nat Mater. 2013 Apr;12(4):367–376.
   PubMed Web of Science ®Google Scholar
• Korschun H. Clinical study at Emory tests microneedle skin patches as alternative to flu shot. 2015. Available from: http://news.emory.edu/stories/2015/08/microneedles_clinical_trial/campus.html
   Google Scholar
• Meek G. Microneedle patch for measles vaccination could be a game changer. Available from: http://www.cdc.gov/media/releases/2015/p0427-microneedle-patch.html
   Google Scholar
• Toon J. NIH awards $10 million to develop microneedle vaccine patch. 2015. Available from: http://www.rh.gatech.edu/news/62737/nih-awards-10-million-develop-microneedle-vaccine-patch
   Google Scholar
• Hirobe S, Azukizawa H, Hanafusa T, et al. Clinical study and stability assessment of a novel transcutaneous influenza vaccination using a dissolving microneedle patch. Biomaterials. 2015 Jul;57:50–58.
   PubMed Web of Science ®Google Scholar